GlassScriptPhysician profile
Peter Tyler Lapen
NPI 1275847717
$3,204.87
in general payments reported to CMS, 2019-2025
28 companies · $36.50 in 2025
The $36.50 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $779 · 2021: $414 · 2022: $813 · 2023: $527 · 2024: $95.73 · 2025: $36.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,386.06 | 2019-2023 | Octrode, Penta |
| Si-Bone, INC. | $343.33 | 2019-2022 | |
| Nevro Corp. | $282.51 | 2020-2023 | Senza |
| Abbvie INC. | $119.02 | 2022-2023 | |
| Boston Scientific Corporation | $101.79 | 2019 | |
| Medtronic, INC. | $100.29 | 2021-2023 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $95.73 | 2024 | Sprint Pns System |
| Ucb, INC. | $74.92 | 2021-2023 | |
| Lilly USA, LLC | $69.33 | 2021-2023 | Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $68.12 | 2022-2023 | |
| Allergan, INC. | $60.93 | 2020-2022 | |
| Medtronic USA, INC. | $56.15 | 2020 | |
| Emd Serono, INC. | $54.89 | 2019 | |
| Banner Life Sciences, LLC | $53.36 | 2022 | |
| Stryker Corporation | $43.52 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $37.51 | 2022-2023 | Ingrezza, Ongentys |
| Avanos Medical | $36.50 | 2025 | Standard Rf Disposables |
| Tanabe Pharma America, INC. | $33.69 | 2023 | |
| Celgene Corporation | $30.78 | 2023 | Zeposia |
| Jazz Pharmaceuticals INC. | $26.48 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.19 | 2023 | Andexxa |
| Sk Life Science, INC. | $19.68 | 2023 | |
| Argenx US, INC. | $18.07 | 2022 | |
| Adamas Pharmaceuticals, INC. | $17.78 | 2020 | |
| Lundbeck LLC | $15.82 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.41 | 2023 | Rytary |
| Avion Pharmaceuticals | $12.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.